About P&T JournalContacts:
Editorial: Sonja Sherritze, Editor
Advertising: Maureen Dwyer Liberti,
Vice President, Group Publisher
Production: Mary Ellen Curry,
Director of Production Services
Circulation: Jackie Ott, Circulation Manager
- 2014 Rate Card & Production Specs
- 2013 Rate Card & Production Specs
- Advertising Due Dates
- BPA Statement
Statement of Purpose
Guidelines for Authors
Sometimes “special” issues just happen.
Dr. Lawless presents a timely tribute to the late Dr. Crick, who discovered the double helix and DNA with a little help from his friends.
Grant D. Lawless, MD, RPh
Some advances in urology include the use of leuprolide and zoledronic acid for prostate cancer; lidocaine for therapy-induced penile aching; alprostadil, vardenafil, and tadalafil for erectile dysfunction; tolterodine and solifenacin for overactive bladder; and a gelatin sealant for tubeless percutaneous nephrolithotomy.
Lawrence M. Prescott, PhD
Gabapentin and Improved Health Status in Elderly Patients with Postherpetic Neuralgia: A Pooled Analysis of Three Clinical Studies
The antiepileptic agent gabapentin (Neurontin®) can be helpful in treating a painful condition that commonly affects older patients.
Brett Stacey, MD, Bruce Parsons, MD, PhD, Sue Huang, Shoshana Peyser, PhD, and Ellen Dukes, PhD
Continuing Education Credit
The authors review the guidelines for and the complexities of administering warfarin, a commonly used antithrombotic agent.
Randolph E. Regal, BS, PharmD, and Vanna Tsui, PharmD
Karl Matuszewski MS, PharmD, describes a physician’s account of his experience with coronary artery
bypass graft surgery.
Karl Matuszewski MS, PharmD
Matthew Grissinger, RPh, FASCP, stresses the importance of appropriate use of fibrinolytic agents in patients with acute myocardial infarction.
Matthew Grissinger, RPh, FASCP
Stephen Barlas discusses the “formulary fireworks” surrounding the draft Medicare guidelines issued by the United States Pharmacopeia.
P&T presents the latest information about FDA approvals, drug indications, industry updates, and new devices
Alfuzosin HCl (Uroxatral®): An Extended-Release Alpha1-Adrenergic Receptor Antagonist for Benign Prostatic Hyperplasia
Drs. Gonzales and Edwards review alfuzosin HCl (Uroxatral®) for the treatment of benign prostatic hyperplasia.
Michelle Gonzales, PharmD, and Deidree Edwards, PharmD